Zenapax

From WikiMD.org
Jump to navigation Jump to search

Zenapax

Zenapax (pronounced: zeh-nuh-pax) is a brand name for the drug Daclizumab, a humanized monoclonal antibody that is primarily used in the prevention of acute rejection in organ transplantation, particularly in kidney transplants.

Etymology

The name "Zenapax" is a brand name and does not have a known etymology. The generic name, Daclizumab, is derived from the combination of "Da" (indicating the species of origin, in this case, human) and "clizu" (indicating the targeted antigen, in this case, the interleukin-2 receptor).

Usage

Zenapax is used to prevent acute rejection of kidney transplants. It works by binding to the interleukin-2 receptor on the surface of activated T-lymphocytes, a type of white blood cell that plays a key role in the immune response to organ transplants. By blocking the action of interleukin-2, Zenapax helps to prevent the body's immune system from attacking the transplanted organ.

Related Terms

  • Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
  • Interleukin-2 receptor: A protein found on the surface of certain immune cells to which interleukin-2 can attach, causing the cells to divide and grow.
  • Acute rejection: A type of organ transplant rejection that occurs when the immune system suddenly begins attacking the transplanted organ.
  • Kidney transplant: A surgical procedure to place a healthy kidney from a live or deceased donor into a person whose kidneys no longer function properly.

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski